Cargando…

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors

SIMPLE SUMMARY: This review summarizes the current knowledge on mesothelin’s function, its role in cancer, and opportunities for immunotherapeutic targeting of mesothelin. Immunotherapies including monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor T and NK-cells, targeted al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faust, Joshua R., Hamill, Darcy, Kolb, Edward Anders, Gopalakrishnapillai, Anilkumar, Barwe, Sonali P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946840/ https://www.ncbi.nlm.nih.gov/pubmed/35326701 http://dx.doi.org/10.3390/cancers14061550

Ejemplares similares

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2014)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
por: Lehner, Kara M., et al.
Publicado: (2023)

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology
por: Barwe, Sonali P., et al.
Publicado: (2020)

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
por: Barwe, Sonali P., et al.
Publicado: (2022)

Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies
por: Quagliano, Anthony, et al.
Publicado: (2023)

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
por: Quagliano, Anthony, et al.
Publicado: (2020)

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies
por: Sidhu, Ishnoor, et al.
Publicado: (2021)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2015)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2016)

Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017)

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring
por: Crowgey, Erin L., et al.
Publicado: (2020)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
por: Zhao, Xiao-Yan, et al.
Publicado: (2016)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples
por: Barwe, Sonali P., et al.
Publicado: (2020)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
por: Mishra, Alok K., et al.
Publicado: (2022)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
por: Zhang, Hongyu, et al.
Publicado: (2022)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment
por: Huynh, Duc, et al.
Publicado: (2022)

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2019)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome
por: Bloh, Kevin M., et al.
Publicado: (2017)

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
por: Hatterer, Eric, et al.
Publicado: (2020)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
por: Hassan, Raffit, et al.
Publicado: (2023)

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
por: Li, Edward
Publicado: (2018)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhojdn2k71u2aa6bmnst4hee81